#NanoString

[cavenewstimes]

NanoString Says Disagrees With Jury's Patent-Infringement Verdict; Withdraws Outlook

(RTTNews) – NanoString Technologies Inc. (NSTG) stated it respectfully disagreed with the decision of the jury in the U.S. District Court for the District of Delaware. The business will look for to have the decision reversed or changed in post-trial movements and after that anticipates to attract the U.S. Court of Appeals for the Federal Circuit, a court that focuses on patent conflicts. On 17th…

[spatialtranscriptomics]

How to Develop a Joint Inflammatory Signature for Osteoarthritis Using Spatial Transcriptomics

Introduction: What is Spatial Transcriptomics?

Spatial transcriptomics is a new field of science that studies the spatial distribution of inflammatory markers in arthritis.

What We Know about Arthritis and Inflammation

Arthritis is a general term for many types of joint problems. It can be caused by a variety of things, including age, injury, or an autoimmune disease.

Inflammation is the body's response to an injury or infection. It helps protect the body from infection and removes damaged tissue. But it can also cause damage to healthy cells and tissues if it lingers too long in one place.

Spatial Transcriptomics is used in the complete analysis of Arthritis and inflammation.

Developing an Inflammatory Signature for Osteoarthritis

Inflammation can be a major factor in the development of osteoarthritis. Joint inflammation is one of the most common symptoms of osteoarthritis. Inflammatory markers can be used to diagnose and monitor osteoarthritis.

Conclusion & Discussion

In this study, we have shown that spatial transcriptomics can be used to identify the underlying molecular mechanisms of arthritic joint pain. This is an important step toward the development of novel therapies for arthritis

[covid-safer-hotties]

Deterioration of neuroimmune homeostasis in Alzheimer’s Disease patients who survive a COVID-19 infection - Published Aug 17, 2024

Abstract Growing evidence has implicated systemic infection as a significant risk factor for the development and advancement of Alzheimer’s disease (AD). With the emergence of SARS-CoV-2 (COVID-19) and the resultant pandemic, many individuals from the same aging population vulnerable to AD suffered a severe systemic infection with potentially unidentified long-term consequences for survivors. To study the impact of COVID-19 survival on the brain’s intrinsic immune system in a population also suffering from AD, we profiled post-mortem brain tissue from patients in the UF Neuromedicine Human Brain and Tissue Bank with a diagnosis of AD who survived a COVID-19 infection (COVID-AD) and contrasted our findings with AD patients who did not experience a COVID-19 infection, including a group of brain donors who passed away before arrival of SARS-CoV-2 in the United States. We assessed disease-relevant protein pathology and microglial and astrocytic markers by quantitative immunohistochemistry and supplemented these data with whole tissue gene expression analysis performed on the NanoString nCounter® platform. COVID-AD patients showed slightly elevated Aβ burden in the entorhinal, fusiform, and inferior temporal cortices compared to non-COVID-AD patients, while tau pathology burden did not differ between groups. Analysis of microglia revealed a significant loss of microglial homeostasis as well as exacerbated microgliosis in COVID-AD patients compared to non-COVID-AD patients in a brain region-dependent manner. Furthermore, COVID-AD patients showed reduced cortical astrocyte numbers, independent of functional subtype. Transcriptomic analysis supported these histological findings and, in addition, identified a dysregulation of oligodendrocyte and myelination pathways in the hippocampus of COVID-AD patients. In summary, our data demonstrate a profound impact of COVID-19 infection on neuroimmune and glial pathways in AD patients persisting for months post-infection, highlighting the importance of peripheral to central neuroimmune crosstalk in neurodegenerative diseases.

[leedsomics]

UCS: a unified approach to cell segmentation for subcellular spatial transcriptomics

Subcellular Spatial Transcriptomics (SST) represents an innovative technology enabling researchers to investigate gene expression at the subcellular level within tissues. To comprehend the spatial architecture of a given tissue, cell segmentation plays a crucial role in attributing the measured transcripts to individual cells. However, existing cell segmentation methods for SST datasets still face challenges in accurately distinguishing cell boundaries due to the varying characteristics of SST technologies. In this study, we propose a unified approach to cell segmentation (UCS) specifically designed for SST data obtained from diverse platforms, including 10X Xenium, NanoString CosMx, MERSCOPE, and Stereo-seq. UCS leverages deep learning techniques to achieve high accuracy in cell segmentation by integrating nuclei segmentation from nuclei staining and transcript data. Compared to current methods, UCS not only provides more precise transcript assignment to individual cells but also offers computational advantages for large-scale SST data analysis. The analysis output of UCS further supports versatile downstream analyses, such as subcellular gene classification and missing cell detection. By employing UCS, researchers gain the ability to characterize gene expression patterns at both the cellular and subcellular levels, leading to a deeper understanding of tissue architecture and function. http://dlvr.it/T9M8Cl

[impact-newswire]

Bruker - We offer high-performance scientific instruments and high-value analytical and diagnostic solutions.

[ramtracking]

Bruker to Acquire NanoString with $392.6M Winning Bid [ Bruker ]

Bruker to Acquire NanoString with $392.6M Winning Bid [News Summary] NanoString Technologies has found a buyer in Bruker, which will acquire substantially all the bankrupt company’s assets for approximately… NanoString Technologies, Inc. (“NanoString” or “the Company”), a leading provider of life science tools for discovery and translational… Bruker has emerged as the winner of an auction for…

[robjackson616-blog]

Precision Medicine  Market to Witness Unbelievable Growth from 2024 to 2030:

According to HTF Market Intelligence, theGlobal Precision Medicine market to witness a CAGR of 12% during forecast period of 2024-2030. Global Precision Medicine Market Breakdown by Application (Diagnostics, Therapeutics, Pharmaceuticals, Medical Devices, Others) by Type (Consumables, Instruments, Services, Others) by Technology (Bioinformatics, Big Data Analytics, Drug Discovery, Gene Sequencing, Companion Diagnostics, Others) and by Geography (North America, South America, Europe, Asia Pacific, MEA). The Precision Medicine market size is estimated to increase by USD xx Services at a CAGR of 12% from 2024 to 2030.. Currently, market value is pegged at USD  Services.

Get Detailed TOC and Overview of Report @

Precision Medicine is an innovative approach to medical treatment and healthcare that takes into account individual differences in patients' genes, environments, and lifestyles. It involves tailoring medical decisions, practices, interventions, and therapies to the characteristics of an individual patient, rather than adopting a one-size-fits-all approach.

Some of the key players profiled in the study are Biocrates Life Sciences AG (Austria), Nanostring Technologies (United States), Intomics (Denmark), Pfizer Inc. (united States), Eagle Genomics Ltd (United Kingdom), Teva Pharmaceuticals (Israel), Laboratory Corporation of America Holdings (United States), Novartis AG (Switzerland), Qiagen NV (Netherlands).

Book Latest Edition of Global Precision Medicine Market Study @ https://www.htfmarketintelligence.com/buy-now?format=1&report=1309

About Us:

HTF Market Intelligence is a leading market research company providing end-to-end syndicated and custom market reports, consulting services, and insightful information across the globe. HTF MI integrates History, Trends, and Forecasts to identify the highest value opportunities, cope with the most critical business challenges and transform the businesses. Analysts at HTF MI focuses on comprehending the unique needs of each client to deliver insights that are most suited to his particular requirements.

Contact Us:

Craig Francis (PR & Marketing Manager) HTF Market Intelligence Consulting Private Limited Phone: +15075562445 sales@htfmarketintelligence.com

[creative-news-alert]

Phosphor Screen Scanner Market is Estimated to Witness High Growth Owing to Increasing Adoption in Radiology and Molecular Diagnostics.

The phosphor screen scanner market consists of medical imaging devices that digitize phosphor screen plates used in radiology and dental applications. Phosphor screens are used in X-ray imaging and store X-ray data as a latent image. Phosphor screen scanners scan these plates and convert the stored X-ray information into a digital format such as DICOM that can be viewed and processed on computers. The devices find widespread application in general radiography, mammography, orthopedic imaging, and dental applications. The global phosphor screen scanner market is estimated to be valued at US$ 288 Bn in 2023 and is expected to exhibit a CAGR of 10.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: One of the major drivers for the growth of the phosphor screen scanner market is the increasing adoption of digital radiology and molecular diagnostics. Digital radiography replaces conventional X-ray film with phosphor screen plates and scanners, offering advantages such as improved image quality, reduced X-ray dosage, and instant image availability. It is widely being adopted across hospitals and diagnostic centers. Furthermore, the rising incidence of chronic diseases such as cancer is leading to increasing diagnostic imaging procedures. This in turn is promoting the demand for phosphor screen scanners in conjunction with X-ray imaging equipment. In addition, technological advancements resulting in more sensitive phosphor screens and high-resolution scanners are further supporting the market growth over the forecast period. SWOT Analysis Strength: The phosphor screen scanner market size has strong growth potential owing to rising demand for digital radiography systems. Phosphor screen scanners offer high-resolution images and are less expensive than traditional systems. They are also portable and allow for quick scanning of images. Weakness: Phosphor screen scanners have some limitations compared to newer digital options. They require specialized phosphor plates and chemicals for developing images. The plates also have a limited useful lifetime and need replacement. Phosphor screen scanners also cannot perform real-time imaging. Opportunity: Growth opportunities exist in emerging markets as healthcare infrastructure improves. Asian countries are expected to see higher adoption rates for phosphor screen scanners. Enhanced models with better image quality and portability also provide room for innovation. Integrating artificial intelligence could help automate image analysis. Threats: Stiff competition exists from newer digital radiography technologies like CR and DR systems. These offer advantages like real-time imaging, lower operating costs, and wider applications. Strict regulations around healthcare technologies also pose compliance challenges. Rising environmental concerns around disposal of phosphor plates act as a restraint. Key Takeaways The global phosphor screen scanner market is expected to witness high growth over the forecast period driven by widespread applications in hospitals, clinics and diagnostic centers.

Regional analysis: The Asia Pacific region holds the leading share of the global phosphor screen scanner market currently. China dominates the APAC market owing to its large population and healthcare sector expansion programs. India is another highly lucrative market and is expected to see a double digit CAGR through 2031. This can be attributed to growing government focus on universal healthcare and increasing investments in medical infrastructure development projects. Key players: Key players operating in the phosphor screen scanner market are Intomics, GENinCode, NanoString, Tepnel Pharma Services Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc, QIAGEN, Quest Diagnostics Incorporated, Medtronic, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, bioMérieux SA, F. Hoffmann-La Roche Ltd, Eli Lilly & Company, GlaxoSmithKline plc, Cepheid, AstraZeneca PLC, Myriad Genetics, Inc., Bristol-Myers Squibb Company, and Foundation Medicine, Inc. These companies are focusing on product launches and partnerships to strengthen their positions.Get more insights on this topic:https://www.newswirestats.com/phosphor-screen-scanner-market-size-and-outlook/

[rnomics]

#cancers, Vol. 16, Pages 423: Mapping the Anti-#cancer Activity of α-Connexin Carboxyl-Terminal (aCT1) Peptide in Resistant HER2+ Breast #cancer

Connexin 43 (Cx43) is a protein encoded by the GJA1 gene and is a component of cell membrane structures called gap junctions, which facilitate intercellular communication. Prior evidence indicates that elevated GJA1 expression in the HER2-positive (HER2+) subtype of breast #cancer is associated with poor prognosis. Prior evidence also suggests that HER2+ breast #cancers that have become refractory to HER2-targeted agents have a loss of Cx43 gap junction intercellular communication (GJIC). In this study, a Cx43-targeted agent called alpha-connexin carboxyl-terminal peptide (aCT1) is examined to determine whether GJIC can be rescued in refractory HER2+ breast #cancer cells. A proposed mechanism of action for aCT1 is binding to the tight junction protein Zonal Occludens-1 (ZO-1). However, the true scope of activity for aCT1 has not been explored. In this study, mass spectrometry proteomic analysis is used to determine the breadth of aCT1-interacting proteins. The NanoString nCounter Breast #cancer 360 panel is also used to examine the effect of aCT1 on #cancer signaling in HER2+ breast #cancer cells. Findings from this study show a dynamic range of binding partners for aCT1, many of which regulate gene expression and #RNA biology. nCounter analysis shows that a number of pathways are significantly impacted by aCT1, including upregulation of apoptotic factors, leading to the prediction and demonstration that aCT1 can boost the cell death effects of cisplatin and lapatinib in HER2+ breast #cancer cells that have become resistant to HER2-targeted agents. https://www.mdpi.com/2072-6694/16/2/423?utm_source=dlvr.it&utm_medium=tumblr

[omkarpatel]

Spatial Genomics Transcriptomics is Estimated to Witness High Growth Owing to Opportunity of Healthcare Advancements

Spatial genomics transcriptomics is an emerging technique which allows simultaneous analysis of RNA expression levels within individual cells in their original tissue context at high resolution. It enables unbiased mapping of the cellular composition of tissues and detecting cell types, states and interactions in situ. The technique combines spatial imaging with sequencing to determine where transcripts are located in fixed and stained tissues. This provides immense advantages over other bulk tissue RNA-seq techniques as it offers spatial context and cellular resolution of gene expression.

The global Spatial Genomics Transcriptomics Market s estimated to be valued at US$ 450 million in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The key opportunity driving the high growth of the spatial genomics transcriptomics market is its potential to advance healthcare. Spatial genomics can unravel the complex interplay between cells in healthy and diseased tissues. This technique is being applied to further understand various disease conditions like cancer at an unprecedented scale and resolution. Researchers are mapping expression of genes in tissues to gain novel insights into development and progression of diseases. Spatial understanding of genetic changes in situ can prove pivotal in discovering biomarkers and designing more precise therapies. Several biopharma companies are investing heavily in spatial genomics to accelerate drug discovery and development efforts. The ability of this technique to provide precise spatial mapping of gene expression holds immense potential to transform healthcare in the coming years. Porter’s Analysis Threat of new entrants: The spatial genomics transcriptomics market requires high capital investment and established distribution channels which poses significant barriers for new players. Bargaining power of buyers: Large pharmaceutical companies have strong bargaining power due to their high volume purchases. However, various product options provide flexibility to buyers. Bargaining power of suppliers: Key technology providers like 10x Genomics have considerable influence over prices and innovations. Nonetheless, their dependence on a small buyer base mitigates bargaining power. Threat of new substitutes: Limited substitutes exist for spatial genomics transcriptomics techniques due to their unique capability to detect molecular profiles of tissues at high resolution. Competitive rivalry: Players like NanoString and Illumina compete intensely on technology advancements, licensing deals and geographic expansions. SWOT Analysis Strength: Spatial genomics transcriptomics provides comprehensive single-cell analysis without requiring cell dissociation. It allows mapping gene expression in anatomical context of tissues. Weakness: High costs, complex workflow and heavy data analysis requirements restrict wider adoption. Challenges remain in achieving optimal resolution, scale and specificity. Opportunity: Growing R&D in genomics, drug discovery and development is stimulating demand. Potential clinical applications include cancer diagnostics, neuroscience and inflammatory diseases. Threats: Stringent regulatory norms and data privacy laws pose compliance issues. Slow commercialization compared to other omics technologies. Key Takeaways The global spatial genomics transcriptomics market is expected to witness high growth. Advancing capabilities to reveal cell-type organization and gene correlations at microanatomical scales will support market rise. The global Spatial Genomics Transcriptomics Market is estimated to be valued at US$ 300 million in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023-2030. North America dominates current demand owing to extensive research and technology development activities in the region. Asia Pacific is likely to be the fastest growing market for spatial genomics transcriptomics during the forecast period. Countries like China, India and South Korea are strengthening genomic research infrastructure which will support technology adoption. Key players: Key players operating in the spatial genomics transcriptomics market are 10x Genomics, NanoString Technologies, Seven Bridges Genomics, Dovetail Genomics, S2 Genomics and others. 10x Genomics has established itself as the market leader by launching product upgrades frequently and filing patents for new techniques.

[blog-site-for-market-research]

Cancer Diagnostics Market Size, Industry Trends and Forecast to 2032

Market Overview

The Cancer Diagnostics Market Size was assessed at USD 160.2 billion in 2021 and is expected to rise from USD 170.9 billion in 2022 to USD 269.1 billion by 2030, with a compound yearly growth rate (CAGR) of 6.70% during the forecast period (2022- 2030). We will provide COVID-19 impact analysis with the report, along with all the extensive key developments in the market post the coronavirus disease outbreak.

Top Boosters and Barriers

Cancer remains of the most common reasons for deaths worldwide and the alarming rate at which it is gaining prevalence is one of the factors that boost the market demand. Given the aggravating situation, healthcare specialists are increasing their focus on developing advanced diagnostic solutions to analyze the prevalence level. Early detection helps increase the treatment’s success rate and therefore, healthcare vendors and the top players armed with awareness campaigns, are busy conducting routine checkups. Other favorable factors can be the rising incidences of oncologic disorders, frequent technological innovations in diagnostics, and the soaring demand for accurate screening tests.

Technological innovations in several fields including imaging, biomarkers, endoscopy; biopsy, and the rapidly expanding geriatric population also work in the cancer diagnostics market’s favor. Rising number of initiatives by the government bodies and the increasing funds being allocated in this field also fosters market growth. But, the significant capital investment required combined with the shortage of skilled medical professionals could deter the market growth in the following years. Having said that, developing healthcare infrastructure across emerging nations and the escalating preference for companion diagnostics offer a host of attractive opportunities to the leading market contenders.

Many of the top firms in the global market are able to sustain their positions by adopting strategies such as product innovations and rigorous R&D efforts for the introduction of the same. It is expected that the competition in the worldwide market could intensify substantially over the next few years, as several vendors are now more focused on carrying out researches and coming up with innovative diagnostic techniques via product range expansions, acquisitions, collaborations and mergers. To illustrate, in November 2020, NanoString Technologies collaborated with the Oregon Health & Science University for the development of GeoMx Digital Spatial Profiler-based protein assays that cater to patients with breast cancer. This product innovation is expected to boost the application range of spatial biology, with the bigger picture being improved patient care via modern molecular testing.

Market Segmentation

Cancer diagnostics industry can be categorized depending on type, application and end user.

The types of cancer diagnostics trend in the market are biomarkers testing, imaging testing, biopsy, in vitro diagnostic testing, and more. Imaging testing types such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scan are non-invasive, pain-free and quick diagnostic solutions and therefore, observe significant demand in the healthcare industry.

Some of the top market applications are breast cancer, lung cancer, melanoma cancer, colorectal cancer, liver cancer, prostate cancer, and others.

Research institutes, hospitals and clinics, diagnostic centers, and others are the key market end-users.

Regional Insight

Asia Pacific or APAC, the Americas, Middle East & Africa or MEA and Europe are the primary markets for cancer diagnostics.

America is currently leading the global market for cancer diagnostics, thanks to the burgeoning elderly population and the high healthcare spending. The well-developed healthcare industry also favors the American market, especially in the United States. The emergence of the latest flow cytometry reagents in terms of diagnostics, growth in government-led initiatives to spread awareness regarding cancer and the strong support of the USFDA with regard to biomarker development are a few other major growth rendering factors in the regional market.

Since 2018, Europe has remained the second biggest market for cancer diagnostics, as a result of the mounting awareness level among people about cancer and the surge in technological advances in the oncology field. The escalating need for advanced diagnostics for the disease also makes Europe a market to watch out for in the coming years. Germany is the frontrunner in the regional market for cancer diagnostics, considering that the country has a massive patient pool and accommodates a huge population of highly skilled healthcare professionals.

APAC could record the highest growth rate in the ensuing years, given that the region holds a vast cancer-afflicted population and this has bolstered the need for more effective diagnostics. This situation is also favored by the constant support of the government that is taking initiatives to improve the healthcare industry in the region. Fast developing economies like India, Japan and China with their thriving manufacturing industries and cheaper production costs, are sparking the interest of several international players that desire to establish their production units in the region.

Top Industry Contenders

Top industry contenders analyzed in the MRFR report include Biotheranostics, Illumina, Inc., Exact Sciences Corporation, QIAGEN N.V., Arquer Diagnostics Ltd, Abbott Laboratories, Inc., Thermo Fisher Scientific, Inc., Roche Diagnostics, Siemens Healthcare, GE Healthcare, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), Koninklijke Philips N.V., Inc., BioMark Diagnostics Inc., Cancer Diagnostics, Inc., to name a few.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com

[unieduvn]

Nanostring nCounter

https://unie.edu.vn/?p=8170 Arizona Genetics Core offers gene expression services using the NanoString nCounter® Analysis Syste...

[fmarkets]

Nanostring Technologies Inc Achieves Impressive Revenue Growth, Driving Reduction in Losses during Q3 20232. https://csimarket.com/stocks/news.php?code=NSTG&date=2023-11-07123536&utm_source=dlvr.it&utm_medium=tumblr

[biotech-news-feed]

Executive and academic appointments, promotions, and departures in omics and molecular diagnostics for the week of Aug. 28, 2023. #BioTech #science

[poonamcmi]

Global Biopharmaceutical and Biomedicine Market Is Estimated To Witness High Growth Owing To Increasing Use of Biological Products

The global Biopharmaceutical and Biomedicine Market is estimated to be valued at US$ 561,375.9 million in 2022 and is expected to exhibit a CAGR of 9.6% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: Biopharmaceutical and biomedicine products are drugs derived from biological sources, including living organisms, cells, and proteins. These products are used to treat various diseases and medical conditions. The market for biopharmaceutical and biomedicine products is driven by the increasing use of biological therapies, which offer numerous advantages over traditional pharmaceuticals, such as targeted treatment, reduced side effects, and enhanced efficacy. B) Market Key Trends: One key trend in the biopharmaceutical and biomedicine market is the growing importance of personalized medicine. Advances in genomics and biotechnology have made it possible to tailor treatment plans to individual patients based on their genetic makeup. This approach allows for more precise and effective treatment, leading to better patient outcomes. For example, the use of monoclonal antibodies in cancer treatment has shown promising results in targeting specific cancer cells and improving survival rates. C) PEST Analysis: Political: Government regulations play a crucial role in the biopharmaceutical and biomedicine industry. Stringent regulations ensure the safety and efficacy of these products, but they can also increase the time and cost associated with development and approval processes. Economic: The demand for biopharmaceutical and biomedicine products is influenced by economic factors such as healthcare expenditure, insurance coverage, and reimbursement policies. Social: The increasing prevalence of chronic diseases and the aging population are driving the demand for biopharmaceutical and biomedicine products. Additionally, patient preferences for targeted and personalized therapies are shaping market trends. Technological: Advances in biotechnology and genomics have revolutionized the field of biopharmaceuticals, enabling the development of innovative products and therapies. D) Key Takeaways: - The global Biopharmaceutical And Biomedicine Market Growth is expected to witness high growth, exhibiting a CAGR of 9.6% over the forecast period. This growth can be attributed to the increasing use of biological products and advancements in personalized medicine. - North America is anticipated to dominate the market, driven by factors such as a well-established healthcare infrastructure, high healthcare expenditure, and favorable regulations. - Key players operating in the global biopharmaceutical and biomedicine market include Amgen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Pfizer Inc., Sanofi, Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol-Myers Squibb Company, NanoString, QIAGEN, Affimed GmbH, GSK plc., Merck KgaA, and Teva Pharmaceutical Industries Ltd. In conclusion, the global biopharmaceutical and biomedicine market is poised for substantial growth due to the increasing use of biological products and the rise in personalized medicine. The market is heavily influenced by political, economic, social, and technological factors. North America is expected to be the fastest-growing and dominating region in this market. Key players in this industry are focused on developing innovative products and therapies to cater to the growing demand for advanced treatments.

[yashvicmi01]

Global Lung Cancer Diagnostic and Screening Market Is Estimated To Witness High Growth Owing To Rising Awareness and Technological Advancements

The global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$ 1,931.0 Mn in 2021 and is expected to exhibit a CAGR of 7.8% over the forecast period 2021-2028, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: Lung cancer diagnostic and screening are crucial in the early detection and treatment of lung cancer. Diagnostic tests such as imaging, biomarker tests, and genetic tests help in the accurate diagnosis of lung cancer. Screening tests such as low-dose computed tomography (LDCT) are used to detect lung cancer in individuals with high-risk factors. These tests play a significant role in improving patient outcomes by enabling early detection and effective treatment. B) Market Dynamics: The two key drivers contributing to the growth of the lung cancer diagnostic and screening market are: 1. Rising Awareness: With the increasing prevalence of lung cancer worldwide, there has been a significant rise in awareness about the importance of early detection and screening. Government initiatives, awareness campaigns, and educational programs have played a crucial role in disseminating information about the risk factors, symptoms, and available diagnostic and screening options for lung cancer. 2. Technological Advancements: Advancements in medical imaging technology, genomics, and molecular biology have revolutionized lung cancer diagnostics and screening. The development of non-invasive biomarker tests, liquid biopsies, and next-generation sequencing techniques has improved the accuracy and efficiency of lung cancer detection. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms in the interpretation of medical images has enhanced diagnostic precision. C) Segment Analysis: One segment dominating the global lung cancer diagnostic and screening market is genetic tests. Genetic tests play a crucial role in identifying specific gene mutations or alterations that are associated with lung cancer. These tests help in determining the appropriate treatment options and predicting treatment response. The increasing demand for personalized medicine and targeted therapies has propelled the growth of the genetic tests segment. D) PEST Analysis: Political: Government initiatives, regulations, and reimbursement policies influence the adoption of lung cancer diagnostic and screening methods. Economic: The economic factors such as healthcare expenditure, insurance coverage, and affordability impact the accessibility of diagnostic and screening services. Social: Increasing awareness, changing lifestyles, and smoking habits influence the demand for lung cancer diagnostic and screening. Technological: Advancements in medical imaging technology, genomics, and molecular biology have improved the accuracy and efficiency of lung cancer diagnostic and screening methods. E) Key Takeaways: - The global Lung Cancer Diagnostic and Screening Market is expected to witness high growth, exhibiting a CAGR of 7.8% over the forecast period, due to increasing awareness about the importance of early detection and screening and advancements in technology. - Among the regional analysis, North America is the fastest-growing and dominating region in the lung cancer diagnostic and screening market, attributed to the high prevalence of lung cancer, well-established healthcare infrastructure, and favorable reimbursement policies. - Key players operating in the global lung cancer diagnostic and screening market include Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. These companies are focused on research and development activities, strategic collaborations, and mergers and acquisitions to strengthen their market position and introduce innovative diagnostic and screening solutions.